 Halis Akturk
Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 82 | 2026 | 3890 | 12.640 |
Why?
| | Blood Glucose Self-Monitoring | 46 | 2026 | 699 | 9.390 |
Why?
| | Hypoglycemic Agents | 49 | 2026 | 1389 | 9.050 |
Why?
| | Blood Glucose | 64 | 2026 | 2330 | 8.370 |
Why?
| | Hypoglycemia | 14 | 2026 | 477 | 5.440 |
Why?
| | Insulin | 42 | 2026 | 2507 | 5.150 |
Why?
| | Insulin Infusion Systems | 25 | 2026 | 477 | 4.740 |
Why?
| | Diabetic Ketoacidosis | 10 | 2026 | 210 | 4.380 |
Why?
| | Hyperglycemia | 5 | 2026 | 375 | 2.720 |
Why?
| | Ketones | 3 | 2026 | 53 | 1.980 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2022 | 199 | 1.810 |
Why?
| | Diabetes Mellitus, Type 2 | 13 | 2025 | 2584 | 1.770 |
Why?
| | Programmed Cell Death 1 Receptor | 4 | 2019 | 264 | 1.580 |
Why?
| | Glucagon-Like Peptides | 4 | 2026 | 70 | 1.470 |
Why?
| | Ketosis | 2 | 2022 | 12 | 1.410 |
Why?
| | Insulins | 3 | 2023 | 38 | 1.390 |
Why?
| | Diabetes Mellitus | 8 | 2026 | 1098 | 1.370 |
Why?
| | Humans | 108 | 2026 | 144957 | 1.290 |
Why?
| | Device Removal | 2 | 2021 | 143 | 1.170 |
Why?
| | Adult | 50 | 2026 | 40506 | 1.140 |
Why?
| | Overweight | 4 | 2026 | 609 | 1.120 |
Why?
| | Insulin, Long-Acting | 5 | 2025 | 65 | 1.090 |
Why?
| | Antibodies, Monoclonal | 3 | 2020 | 1524 | 1.070 |
Why?
| | Pancreas, Artificial | 3 | 2025 | 97 | 1.060 |
Why?
| | Insulin, Short-Acting | 2 | 2026 | 8 | 1.010 |
Why?
| | Weight Loss | 7 | 2026 | 837 | 0.920 |
Why?
| | Obesity | 7 | 2026 | 3082 | 0.880 |
Why?
| | Glucagon | 2 | 2025 | 113 | 0.870 |
Why?
| | Thyrotoxicosis | 1 | 2024 | 7 | 0.870 |
Why?
| | Middle Aged | 34 | 2026 | 35928 | 0.850 |
Why?
| | Melanoma | 2 | 2022 | 761 | 0.820 |
Why?
| | Cannabis | 3 | 2022 | 509 | 0.800 |
Why?
| | Male | 47 | 2026 | 72406 | 0.790 |
Why?
| | Sweetening Agents | 1 | 2023 | 57 | 0.760 |
Why?
| | Testosterone | 2 | 2017 | 419 | 0.760 |
Why?
| | Cell Cycle Checkpoints | 2 | 2020 | 99 | 0.730 |
Why?
| | Female | 44 | 2026 | 78376 | 0.710 |
Why?
| | Registries | 4 | 2025 | 2385 | 0.710 |
Why?
| | Software | 2 | 2024 | 692 | 0.700 |
Why?
| | HLA-DR Antigens | 1 | 2022 | 220 | 0.700 |
Why?
| | Blindness | 1 | 2020 | 52 | 0.620 |
Why?
| | B7-H1 Antigen | 2 | 2019 | 241 | 0.590 |
Why?
| | Young Adult | 16 | 2026 | 14126 | 0.580 |
Why?
| | Postprandial Period | 2 | 2024 | 118 | 0.570 |
Why?
| | Prostheses and Implants | 1 | 2020 | 141 | 0.570 |
Why?
| | Biosensing Techniques | 1 | 2020 | 139 | 0.540 |
Why?
| | Pregnancy in Diabetics | 1 | 2019 | 121 | 0.530 |
Why?
| | Sulfonylurea Compounds | 1 | 2018 | 51 | 0.530 |
Why?
| | Thyroid Hormones | 1 | 2018 | 67 | 0.530 |
Why?
| | Nonprescription Drugs | 1 | 2018 | 65 | 0.520 |
Why?
| | Osteomalacia | 1 | 2017 | 3 | 0.510 |
Why?
| | Wolfram Syndrome | 1 | 2017 | 5 | 0.510 |
Why?
| | Hypoparathyroidism | 1 | 2017 | 7 | 0.510 |
Why?
| | Eunuchism | 1 | 2016 | 3 | 0.510 |
Why?
| | Thyroidectomy | 1 | 2017 | 91 | 0.500 |
Why?
| | Immunologic Factors | 1 | 2019 | 255 | 0.490 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2025 | 1416 | 0.490 |
Why?
| | Administration, Inhalation | 5 | 2026 | 575 | 0.480 |
Why?
| | Hypogonadism | 1 | 2017 | 90 | 0.480 |
Why?
| | Treatment Outcome | 13 | 2025 | 11695 | 0.470 |
Why?
| | Retrospective Studies | 13 | 2026 | 17101 | 0.470 |
Why?
| | Hormone Replacement Therapy | 1 | 2016 | 106 | 0.460 |
Why?
| | Graft Rejection | 1 | 2018 | 540 | 0.440 |
Why?
| | Telemedicine | 1 | 2024 | 948 | 0.440 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 479 | 0.430 |
Why?
| | Quality of Life | 3 | 2023 | 3192 | 0.430 |
Why?
| | Elephantiasis | 1 | 2014 | 3 | 0.420 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 970 | 0.410 |
Why?
| | Exercise | 1 | 2026 | 2201 | 0.400 |
Why?
| | Dietary Supplements | 1 | 2018 | 576 | 0.400 |
Why?
| | Cryptogenic Organizing Pneumonia | 1 | 2013 | 19 | 0.390 |
Why?
| | Thyroid Neoplasms | 1 | 2017 | 346 | 0.380 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2013 | 33 | 0.380 |
Why?
| | Diabetic Retinopathy | 2 | 2025 | 208 | 0.350 |
Why?
| | Alcohol Drinking | 1 | 2017 | 826 | 0.320 |
Why?
| | Adolescent | 12 | 2026 | 22453 | 0.310 |
Why?
| | Cardiovascular Diseases | 2 | 2017 | 2171 | 0.280 |
Why?
| | Body Mass Index | 5 | 2025 | 2438 | 0.270 |
Why?
| | Self-Injurious Behavior | 2 | 2020 | 142 | 0.270 |
Why?
| | Technology | 3 | 2023 | 96 | 0.260 |
Why?
| | Drug Therapy, Combination | 3 | 2026 | 1048 | 0.260 |
Why?
| | Neoplasms | 2 | 2020 | 2884 | 0.250 |
Why?
| | Case-Control Studies | 2 | 2026 | 3608 | 0.250 |
Why?
| | Risk Factors | 7 | 2025 | 10792 | 0.230 |
Why?
| | Longitudinal Studies | 4 | 2026 | 2947 | 0.230 |
Why?
| | Child | 9 | 2026 | 22657 | 0.230 |
Why?
| | Immunotherapy | 2 | 2020 | 657 | 0.210 |
Why?
| | Norway | 1 | 2024 | 45 | 0.210 |
Why?
| | Weight Gain | 2 | 2018 | 559 | 0.210 |
Why?
| | Proof of Concept Study | 1 | 2024 | 85 | 0.200 |
Why?
| | Health Care Surveys | 1 | 2025 | 539 | 0.190 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 1990 | 0.190 |
Why?
| | Receptors, Glucagon | 1 | 2022 | 26 | 0.190 |
Why?
| | Time Factors | 2 | 2024 | 7183 | 0.190 |
Why?
| | Diagnosis, Differential | 3 | 2017 | 1495 | 0.180 |
Why?
| | Goals | 1 | 2024 | 184 | 0.180 |
Why?
| | Prediabetic State | 1 | 2025 | 245 | 0.180 |
Why?
| | Suicide | 2 | 2020 | 720 | 0.180 |
Why?
| | Ketone Bodies | 1 | 2021 | 15 | 0.180 |
Why?
| | 3-Hydroxybutyric Acid | 1 | 2021 | 17 | 0.170 |
Why?
| | Mobile Applications | 1 | 2024 | 196 | 0.170 |
Why?
| | Gastric Emptying | 1 | 2021 | 36 | 0.170 |
Why?
| | Reference Standards | 1 | 2021 | 178 | 0.170 |
Why?
| | Breath Tests | 1 | 2021 | 79 | 0.170 |
Why?
| | Infrared Rays | 1 | 2021 | 27 | 0.170 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1054 | 0.160 |
Why?
| | Energy Intake | 1 | 2023 | 500 | 0.160 |
Why?
| | Health Behavior | 2 | 2023 | 786 | 0.160 |
Why?
| | Islets of Langerhans | 1 | 2026 | 833 | 0.150 |
Why?
| | Gastroparesis | 1 | 2019 | 9 | 0.150 |
Why?
| | Alleles | 1 | 2022 | 881 | 0.150 |
Why?
| | Body Weight | 1 | 2024 | 978 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2024 | 1095 | 0.150 |
Why?
| | Autoantibodies | 1 | 2026 | 1504 | 0.140 |
Why?
| | Insulin Aspart | 1 | 2018 | 30 | 0.140 |
Why?
| | Glycosides | 1 | 2018 | 42 | 0.140 |
Why?
| | Glucosides | 1 | 2018 | 55 | 0.140 |
Why?
| | Injections | 1 | 2018 | 197 | 0.130 |
Why?
| | Prospective Studies | 4 | 2025 | 7997 | 0.130 |
Why?
| | Benzhydryl Compounds | 1 | 2018 | 82 | 0.130 |
Why?
| | Prevalence | 3 | 2023 | 2836 | 0.130 |
Why?
| | United States Food and Drug Administration | 1 | 2018 | 205 | 0.130 |
Why?
| | Antidiuretic Agents | 1 | 2017 | 5 | 0.130 |
Why?
| | Cost of Illness | 1 | 2019 | 321 | 0.130 |
Why?
| | Ergolines | 1 | 2016 | 3 | 0.130 |
Why?
| | Marijuana Abuse | 1 | 2019 | 211 | 0.120 |
Why?
| | Dopamine Agonists | 1 | 2016 | 42 | 0.120 |
Why?
| | Self Care | 1 | 2019 | 389 | 0.120 |
Why?
| | Osteosarcoma | 1 | 2017 | 76 | 0.120 |
Why?
| | Prolactin | 1 | 2016 | 89 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 988 | 0.120 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2017 | 117 | 0.120 |
Why?
| | Hydrocortisone | 1 | 2018 | 304 | 0.120 |
Why?
| | Patient Admission | 1 | 2018 | 218 | 0.120 |
Why?
| | Marijuana Smoking | 1 | 2019 | 250 | 0.120 |
Why?
| | Risk Assessment | 3 | 2026 | 3676 | 0.120 |
Why?
| | Health Services Accessibility | 1 | 2024 | 1099 | 0.120 |
Why?
| | Double-Blind Method | 3 | 2026 | 2029 | 0.110 |
Why?
| | Health Personnel | 1 | 2022 | 748 | 0.110 |
Why?
| | Reproducibility of Results | 4 | 2025 | 3415 | 0.110 |
Why?
| | United States | 4 | 2025 | 15988 | 0.110 |
Why?
| | Drug Delivery Systems | 1 | 2018 | 381 | 0.110 |
Why?
| | Pituitary Neoplasms | 1 | 2016 | 190 | 0.110 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5872 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2017 | 256 | 0.110 |
Why?
| | Peptostreptococcus | 1 | 2014 | 2 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1721 | 0.110 |
Why?
| | Lymphedema | 1 | 2014 | 24 | 0.100 |
Why?
| | Endocarditis, Bacterial | 1 | 2014 | 44 | 0.100 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2025 | 146 | 0.100 |
Why?
| | Mitral Valve Insufficiency | 1 | 2014 | 72 | 0.100 |
Why?
| | Heart Diseases | 1 | 2017 | 350 | 0.100 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2014 | 70 | 0.100 |
Why?
| | Biomarkers | 1 | 2025 | 4275 | 0.100 |
Why?
| | Age Factors | 2 | 2019 | 3335 | 0.100 |
Why?
| | Prognosis | 2 | 2020 | 4293 | 0.100 |
Why?
| | TRPC Cation Channels | 1 | 2012 | 14 | 0.090 |
Why?
| | Pilot Projects | 1 | 2018 | 1890 | 0.090 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2012 | 90 | 0.090 |
Why?
| | Lymphokines | 1 | 2012 | 130 | 0.090 |
Why?
| | Autoimmunity | 1 | 2018 | 927 | 0.090 |
Why?
| | Incidence | 1 | 2019 | 2883 | 0.090 |
Why?
| | Sex Characteristics | 1 | 2017 | 791 | 0.090 |
Why?
| | Kidney Transplantation | 1 | 2018 | 704 | 0.090 |
Why?
| | Cough | 1 | 2013 | 124 | 0.090 |
Why?
| | Radiography, Thoracic | 1 | 2013 | 171 | 0.090 |
Why?
| | Hemodynamics | 1 | 2017 | 1121 | 0.090 |
Why?
| | Neuroprotective Agents | 1 | 2012 | 143 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2018 | 847 | 0.080 |
Why?
| | Acute Coronary Syndrome | 1 | 2014 | 293 | 0.080 |
Why?
| | Pregnancy | 2 | 2022 | 7191 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1322 | 0.080 |
Why?
| | Biopsy | 1 | 2013 | 1077 | 0.070 |
Why?
| | Blood Pressure | 1 | 2016 | 1769 | 0.070 |
Why?
| | Colorado | 1 | 2019 | 4564 | 0.070 |
Why?
| | Chronic Disease | 1 | 2014 | 1813 | 0.070 |
Why?
| | Hospitalization | 1 | 2018 | 2434 | 0.070 |
Why?
| | Hypertension | 1 | 2016 | 1264 | 0.070 |
Why?
| | Algorithms | 2 | 2025 | 1839 | 0.060 |
Why?
| | Zinc Transporter 8 | 1 | 2026 | 70 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 6053 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2018 | 2920 | 0.060 |
Why?
| | Hypoxia | 1 | 2013 | 1199 | 0.060 |
Why?
| | Age of Onset | 1 | 2026 | 551 | 0.050 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2024 | 13 | 0.050 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2024 | 16 | 0.050 |
Why?
| | Apoptosis | 1 | 2012 | 2430 | 0.050 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 88 | 0.050 |
Why?
| | Meals | 1 | 2024 | 130 | 0.050 |
Why?
| | Transaminases | 1 | 2022 | 22 | 0.050 |
Why?
| | Life Style | 1 | 2025 | 479 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2024 | 601 | 0.050 |
Why?
| | Lipoproteins, LDL | 1 | 2022 | 119 | 0.040 |
Why?
| | Needles | 1 | 2022 | 62 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 405 | 0.040 |
Why?
| | Fear | 1 | 2023 | 366 | 0.040 |
Why?
| | Animals | 3 | 2018 | 38109 | 0.040 |
Why?
| | Child, Preschool | 2 | 2025 | 11799 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2024 | 367 | 0.040 |
Why?
| | Skin | 1 | 2022 | 758 | 0.030 |
Why?
| | Disease Progression | 1 | 2025 | 2852 | 0.030 |
Why?
| | Aged | 3 | 2026 | 25947 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1049 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2024 | 1177 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2018 | 750 | 0.030 |
Why?
| | Quality Improvement | 1 | 2023 | 1291 | 0.030 |
Why?
| | Ceftriaxone | 1 | 2014 | 21 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2019 | 717 | 0.030 |
Why?
| | Global Health | 1 | 2017 | 401 | 0.030 |
Why?
| | Vancomycin | 1 | 2014 | 93 | 0.020 |
Why?
| | Echocardiography, Transesophageal | 1 | 2014 | 133 | 0.020 |
Why?
| | ATPases Associated with Diverse Cellular Activities | 1 | 2012 | 9 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2013 | 64 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2012 | 25 | 0.020 |
Why?
| | Mutation | 1 | 2024 | 4099 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2012 | 72 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2012 | 81 | 0.020 |
Why?
| | Insulin Glargine | 1 | 2013 | 88 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2022 | 5417 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2738 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2012 | 159 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2012 | 196 | 0.020 |
Why?
| | Neuroblastoma | 1 | 2012 | 174 | 0.020 |
Why?
| | Dementia | 1 | 2012 | 304 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1733 | 0.020 |
Why?
| | Calcium | 1 | 2012 | 1184 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2014 | 1209 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3550 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5614 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1915 | 0.010 |
Why?
| | Neurons | 1 | 2012 | 1642 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5233 | 0.010 |
Why?
| | HIV Infections | 1 | 2012 | 3154 | 0.010 |
Why?
|
|
Akturk's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|